Airway dysfunction in nasal polyposis: A spectrum of asthmatic disease?

Clinical and Experimental Allergy

Volumn 41, Issue 10, 2011, Pages 1379-1385

  Williamson, P A ^a   Vaidyanathan, S ^a   Clearie, K ^a   Barnes, M ^a   Lipworth, B J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma; Nasal polyps; Sinusitis

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; NITRIC OXIDE; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; BRONCHUS HYPERREACTIVITY; CHRONIC DISEASE; CHRONIC RHINOSINUSITIS WITH NASAL POLYP; CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENDOSCOPY; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOSINUSITIS; SPIROMETRY;

ADULT; ASTHMA; BRONCHI; BRONCHIAL HYPERREACTIVITY; CHRONIC DISEASE; EOSINOPHILS; EXHALATION; FEMALE; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION; MALE; MIDDLE AGED; NASAL POLYPS; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; RHINITIS; SINUSITIS;

EID: 80052969635     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03793.x     Document Type: Article

References (34)

1. Cruz AA, Popov T, Pawankar Ret al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007; 62(Suppl. 84):1-41.
2. Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T.The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57:1048-52.
3. Bugiani M, Carosso A, Migliore Eet al. Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy. Allergy 2005; 60:165-70.
4. Danielsson J, Jessen M.The natural course of allergic rhinitis during 12 years of follow-up. Allergy 1997; 52:331-4.
5. Braunstahl GJ, Hellings PW.Nasobronchial interaction mechanisms in allergic airways disease. Curr Opin Otolaryngol Head Neck Surg 2006; 14:176-82.
6. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ.Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161:2051-7.
7. Braunstahl GJ, Overbeek SE, Fokkens WJet al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001; 164:858-65.
8. Shaaban R, Zureik M, Soussan Det al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008; 372:1049-57.
9. Magnan A, Meunier JP, Saugnac C, Gasteau J, Neukirch F.Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy 2008; 63:292-8.
10. Settipane RJ, Hagy GW, Settipane GA.Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15:21-5.
11. Ciprandi G, Cirillo I, Pistorio A.Impact of allergic rhinitis on asthma: effects on spirometric parameters. Allergy 2008; 63:255-60.
12. Guilemany JM, Angrill J, Alobid Iet al. United airways again: high prevalence of rhinosinusitis and nasal polyps in bronchiectasis. Allergy 2009; 64:790-7.
13. Hens G, Vanaudenaerde BM, Bullens DMet al. Sinonasal pathology in nonallergic asthma and COPD: 'united airway disease' beyond the scope of allergy. Allergy 2008; 63:261-7.
14. Fokkens W, Lund V, Mullol J.European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007; 20:1-136.
15. Larsen K. The clinical relationship of nasal polyps to asthma. Allergy Asthma Proc 1996; 17:243-9.
16. Lamblin C, Brichet A, Perez T, Darras J, Tonnel AB, Wallaert B.Long-term follow-up of pulmonary function in patients with nasal polyposis. Am J Respir Crit Care Med 2000; 161(Part 1):406-13.
17. Lildholdt T, Rundcrantz H, Lindqvist N.Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin OtolaryngolAllied Sci 1995; 20:26-30.
18. Crapo RO, Casaburi R, Coates ALet al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309-29.
19. Miller MR, Hankinson J, Brusasco Vet al. Standardisation of spirometry. Eur Respir J 2005; 26:319-38.
20. Wanger J, Clausen JL, Coates Aet al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26:511-22.
21. ATS Board of Directors and ERS Committee. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2004. Am J Respir Crit Care Med 2005; 171:912-30.
22. Delclaux C, Malinvaud D, Chevalier-Bidaud B, Callens E, Mahut B, Bonfils P.Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis. Clin Exp Allergy 2008; 38:1140-7.
23. Sont JK, Han J, van Krieken JMet al. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996; 51:496-502.
24. Lex C, Ferreira F, Zacharasiewicz Aet al. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med 2006; 174:1286-91.
25. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ.Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91-5.
26. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC.Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003; 326:1115.
27. Olin AC, Bake B, Toren K.Fraction of exhaled nitric oxide at 50mL/s: reference values for adult lifelong never-smokers. Chest 2007; 131:1852-6.
28. Travers J, Marsh S, Aldington Set al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007; 176:238-42.
29. Ciprandi G, Cirillo I, Klersy Cet al. Role of FEF25-75 as an early marker of bronchial impairment in patients with seasonal allergic rhinitis. Am J Rhinol 2006; 20:641-7.
30. Ciprandi G, Cirillo I, Vizzaccaro A, Monardo M, Tosca MA.Early bronchial airflow impairment in patients with persistent allergic rhinitis and bronchial hyperreactivity. Respir Med 2005; 99:1606-12.
31. Marseglia GL, Cirillo I, Vizzaccaro Aet al. Role of forced expiratory flow at 25-75% as an early marker of small airways impairment in subjects with allergic rhinitis. Allergy Asthma Proc 2007; 28:74-8.
32. Scavuzzo MC, Fattori B, Ruffoli Ret al. Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis. Biomed Pharmacother 2005; 59:323-9.
33. Houghton CM, Woodcock AA, Singh D.A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. Br J Clin Pharmacol 2005; 59:152-9.
34. Ediger D, Sin BA, Heper A, Anadolu Y, Misirligil Z.Airway inflammation in nasal polyposis: immunopathological aspects of relation to asthma. Clin Exp Allergy 2005; 35:319-26.